| Trial ID: | L4609 |
| Source ID: | NCT03064841
|
| Associated Drug: |
No Treatment
|
| Title: |
Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT03064841/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: No Treatment
|
| Outcome Measures: |
Primary: Percentage of Patients Attained Blood Glucose Control Target Defined as Glycated Haemoglobin A1c (HbA1c)<7%, According to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) Guidelines., The percentage of patients attaining blood glucose control target defined as HbA1c\<7%, according to 2015 American Diabetes Association (ADA) and 2013 Chinese Diabetes Society (CDS) guidelines., At study visit (one day) | Secondary: Renal Function Level of Patients Measured by Albuminuria, The renal function level of patients was measured by albuminuria into following categories - normal, micro-albuminuria, macro-albuminuria and missing data. Albuminuria was measured using either as a random spot urine sample, a 24-h urine sample, or a timed urine sample. Normal was defined as \< 30 mg/g, \<30 mg/24h, and \< 20 μg/min with the random spot urine sample, the 24-h urine sample, and the timed urine sample, respectively. Micro-albuminuria was defined as 30 - 300 mg/g, 30 - 300 mg/24h, and 20 - 200 μg/min with the random spot urine sample, the 24-h urine sample, and the timed urine sample, respectively. Macro-albuminuria was defined as \>300 mg/g, \>300 mg/24h, and \>200 μg/min with the random spot urine sample, the 24-h urine sample, and the timed urine sample, respectively., At study visit (one day)|Renal Function Level of Patients Measured by Estimated Glomerular Filtration Rate (eGFR), The renal function level of patients was measured by estimated glomerular filtration rate (eGFR)., At study visit (one day)|Renal Function Level of Patients Measured by Chronic Kidney Disease (CKD) Stage, The renal function level of patients was measured by CKD into following categories - eGFR ≥ 60 milliLitre/minute/1.73 meter \^ 2 (mL/min/1.73m\^2), eGFR \< 60 mL/min/1.73m\^2 and missing data., At study visit (one day)|Treatment Regimens for T2DM That Patient Are Currently Taking, The treatment regimens for T2DM that patient are currently taking., At study visit (one day)|Percentage of Patients Macro-vascular and Micro-vascular Diabetic Complications, The percentage of patients macro-vascular and micro-vascular diabetic complications., At study visit (one day)|Percentage of Patients With Hypoglycaemic Occurrence, The percentage of patients with hypoglycaemic occurrence., At study visit (one day)|Percentage of Patients With Hypoglycaemia Leading to Therapy Change, The percentage of patients with hypoglycaemia leading to therapy change., At study visit (one day)|Percentage of Patients With Anti-hypertension Therapy Usage, The percentage of patients with anti-hypertension therapy usage., At study visit (one day)|Percentage of Patients With Lipid Lowering Therapy Usage, The percentage of patients with lipid lowering therapy usage., At study visit (one day)|Percentage of Patients With Anti-platelet Therapy Usage, The percentage of patients with anti-platelet therapy usage., At study visit (one day)|Follow up Duration of Type 2 Diabetes Related Risk Factors in Clinical Practice, The follow up duration of type 2 diabetes related risk factors was summarized using the situation of lab test including serum creatinine, uric acid, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglyceride and total cholesterol., At study visit (one day)
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1537
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2017-03-09
|
| Completion Date: |
2017-12-30
|
| Results First Posted: |
2019-08-28
|
| Last Update Posted: |
2019-08-28
|
| Locations: |
Peking University Shougang Hospital, Beijing, 100043, China|Beijing Hospital, Beijing, China|Beijing Pinggu Hospital, Beijing, China|China Meitan General Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Chinese Traditional Medicine Hospital of Sichuna Provinc, Chengdu, 610000, China|West China Hospital, Chengdu, 610041, China|First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China|Forth Clinical Hospital of Harbin Medical University, Harbin, China|The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China|Nanjing First Hospital, Nanjing, 210006, China|Integrated Chinese and Western Medicine Hospital, Nanjing, 210029, China|Affiliated Hospital of Nantong University, Nantong, China|The affiliated hospital of medicalcollege qingdao university, Qingdao, 266005, China|Shengjing Hospital of China Medical University, Shenyang, 110072, China|Shenzhen People's Hospital, Shenzhen, 518020, China|The First Affiliated Hospital of Soochow University, Suzhou, 215006, China
|
| URL: |
https://clinicaltrials.gov/show/NCT03064841
|
